<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04002401</url>
  </required_header>
  <id_info>
    <org_study_id>KT-US-471-0114</org_study_id>
    <secondary_id>2019-004803-11</secondary_id>
    <nct_id>NCT04002401</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Either Rituximab or Lenalidomide in Participants With Refractory Large B-Cell Lymphoma</brief_title>
  <acronym>ZUMA-14</acronym>
  <official_title>A Phase 2 Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Either Rituximab or Lenalidomide in Subjects With Refractory Large B-Cell Lymphoma (ZUMA-14)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to estimate the efficacy of axicabtagene ciloleucel in
      combination with either rituximab or lenalidomide, as measured by assessment of response
      rates in adult participants with relapsed/refractory large B-cell lymphoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 5, 2019</start_date>
  <completion_date type="Anticipated">September 2036</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Response (CR) Rate</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>CR rate is defined as the incidence of a CR per the Lugano Classification as determined by study investigators.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing Adverse Events and Clinically Significant Changes in Safety Lab Values</measure>
    <time_frame>Up to 15 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Time Frame: Up to 2 years</time_frame>
    <description>ORR is defined as the incidence of either a CR or a partial response (PR) per the Lugano Classification as determined by study investigators.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>DOR is defined only for participants who experience an objective response and is the time from the first objective response to disease progression per the Lugano Classification as determined by study investigators or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>PFS is defined as the time from the axicabtagene ciloleucel infusion date to the date of disease progression per Lugano Classification as determined by study investigators or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>OS is defined as the time from axicabtagene ciloleucel infusion to the date of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of Axicabtagene Ciloleucel in Blood</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Refractory Large B-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Axicabtagene Ciloleucel and Rituximab Combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive rituximab, and fludarabine and cyclophosphamide conditioning chemotherapy, followed by axicabtagene ciloleucel and additional rituximab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Axicabtagene Ciloleucel and Lenalidomide Combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive lenalidomide, and fludarabine and cyclophosphamide conditioning chemotherapy, followed by axicabtagene ciloleucel and additional lenalidomide.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Axicabtagene Ciloleucel</intervention_name>
    <description>A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously</description>
    <arm_group_label>Axicabtagene Ciloleucel and Lenalidomide Combination</arm_group_label>
    <arm_group_label>Axicabtagene Ciloleucel and Rituximab Combination</arm_group_label>
    <other_name>Yescarta速</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Administered intravenously</description>
    <arm_group_label>Axicabtagene Ciloleucel and Rituximab Combination</arm_group_label>
    <other_name>RITUXAN速</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Capsule(s) administered orally with or without food</description>
    <arm_group_label>Axicabtagene Ciloleucel and Lenalidomide Combination</arm_group_label>
    <other_name>REVLIMID速</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Administered according to package insert</description>
    <arm_group_label>Axicabtagene Ciloleucel and Lenalidomide Combination</arm_group_label>
    <arm_group_label>Axicabtagene Ciloleucel and Rituximab Combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Administered according to package insert</description>
    <arm_group_label>Axicabtagene Ciloleucel and Lenalidomide Combination</arm_group_label>
    <arm_group_label>Axicabtagene Ciloleucel and Rituximab Combination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Histologically confirmed large B-cell lymphoma

          -  Chemotherapy-refractory disease, defined as one or more of the following:

               -  No response to first-line therapy (primary refractory disease)

               -  No response to second or greater lines of therapy OR

               -  Refractory after autologous stem cell transplant (ASCT)

          -  At least 1 measureable lesion according to the Lugano Classification (Cheson 2014).

          -  Individuals must have received adequate prior therapy, including at a minimum:

               -  Anti-CD20 monoclonal antibody

               -  An anthracycline-containing chemotherapy regimen

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Adequate renal, hepatic, pulmonary, and cardiac function

          -  Individuals must be able to comply with relevant, equivalent requirements adopted from
             the REVLIMID Risk Evaluation and Mitigation Strategy (REMS)速 (United States) or
             additional Risk Minimization Measures (aRMMs) as part of the Risk Management Plan
             (RMP) (European Union)

        Key Exclusion Criteria:

          -  Known CD19 negative or CD20 negative tumor

          -  History of Richter's transformation of Chronic Lymphocytic Leukemia (CLL)

          -  Prior lenalidomide or other immunomodulatory imide drug (IMiD) treatment

          -  Prior CAR therapy or other genetically modified T-cell therapy

          -  Prior organ transplantation including prior allogeneic stem cell transplant (SCT)

          -  Prior CD19 targeted therapy

          -  Clinically significant infection or cardiopulmonary disease

          -  Presence of any in-dwelling lines or drains (dedicated central venous access catheters
             allowed)

          -  History or presence of central nervous system (CNS) lymphoma or nonmalignant CNS
             disorder or cerebrospinal fluid (CSF) malignant cells or brain metastases

          -  History of autoimmune disease

          -  History of deep vein thrombosis (DVT) or pulmonary embolism (PE) within the last year

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kite Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Kite, A Gilead Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Medical Information</last_name>
    <phone>1-844-454-5483(1-844-454-KITE)</phone>
    <email>medinfo@kitepharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Banner MD Anderson Cancer Center</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Institute</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCLA Hematology/Oncology</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center at Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center, New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. David's South Austin Medical Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 27, 2019</study_first_submitted>
  <study_first_submitted_qc>June 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2019</study_first_posted>
  <last_update_submitted>June 25, 2020</last_update_submitted>
  <last_update_submitted_qc>June 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

